PT  - JOURNAL ARTICLE
AU  - Nnaemeka, Victory Chizaram
AU  - Okafor, Nnenna Audrey
AU  - Orababar, Oluwatosin Qawiyy
AU  - Anikwe, Ruth
AU  - Onwe, Reuben Ogba
AU  - Uzochukwu, Nneka Patricia
AU  - Tsiterimam, Thomas Sambo
AU  - Nwokoye, Nkiru Nenye
AU  - Ike, Anthony Chibuogwu
TI  - COVID-19 Vaccine Acceptance in Nigeria: A Rapid Systematic Review and Meta-Analysis
AID  - 10.1101/2023.02.16.23286008
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.02.16.23286008
4099  - http://medrxiv.org/content/early/2023/02/16/2023.02.16.23286008.short
4100  - http://medrxiv.org/content/early/2023/02/16/2023.02.16.23286008.full
AB  - Widespread COVID-19 vaccination is essential to maintaining pandemic control. However, low- and lower-middle-income countries (LMICs) continue to face challenges to care due to unequal access and vaccine fear despite the introduction of safe and effective immunizations. This study aimed to collect information on Nigeria’s COVID-19 vaccine uptake rates and determinants. Science Direct, PubMed, Google Scholar, African Journal Online, Springer, and Hinari were all systematically searched through and completed in May 2022. Quality assessments of the listed studies were performed using the eight-item Joanna Briggs Institute Critical Appraisal tools for cross-sectional studies. In addition, we undertook a meta-analysis to calculate pooled acceptance rates with 95% confidence intervals (CI). Forty-two studies in total satisfied the inclusion criteria and were reviewed. A total of 24,533 respondents were studied. The total sample size of states in the Northern, Western and Southern parts of Nigeria are 3,206, 4,527 and 5,059, respectively, while 11,741 is the cumulative sample size of all the Nigeria-wide studies. The total COVID-19 vaccination acceptance rate among all the study groups was 52.4% (95% CI: 46.9-57.9%, I2 = 100%), while the total estimated COVID-19 vaccination hesitancy rates was 47.81% (95% CI: 42.2 – 53.4% I2 = 100%). In Nigeria-regions sub-group analyses, the Western region (58.90%, 95% CI: 47.12–70.27%) and Northern region (54.9%, 95% CI: 40.11%–69.4%) showed the highest rates of vaccine acceptance and vaccine hesitancy respectively. The COVID-19 vaccine acceptance rate was highest in 2020, with a pooled rate of 59.56% (46.34, 57.32%, I2 = 98.7%). The acceptance rate in 2021 was only 48.48 (40.78%, 56.22%), while for the studies in 2022, it increased to 52.04% (95% CI: 35.7%, 68.15 %). The sensitization of local authorities and the dissemination of more detailed information about the COVID-19 vaccine and its safety, could significantly increase the country’s vaccination rate.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:A systematic search was conducted in Science Direct, PubMed, Google Scholar, African Journal Online, Springer and Hinari. Keywords in various parenthesis permutations such as COVID-19, VACCINE, ACCEPTANCE, and NIGERIA, COVID-19 VACCINE, ACCEPTANCE, NIGERIA, COVID-19, VACCINE ACCEPTANCE, COVID-19 VACCINE ACCEPTANCE, NIGERIA VACCINE HESITANCY, NIGERIA WEST AFRICA, were used. Boolean operators such as (AND, NOT, OR) were also used. Finally, all the identified articles were downloaded into Zotero bibliographic management software for further processing. The last search for the studies was conducted on May 31, 2022. Further details on the search methods are described in the supplementary material.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript https://drive.google.com/file/d/1ja5dX1wM8lBVTfRMxofwEa5LGdZHZ17q/view?usp=share_link.